Lexicon Pharmaceuticals | LXRX - Gross Profit On Sales


Lexicon Pharmaceuticals reported $5.29M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Abbott USD 6.54B 625M Dec/2025
Acadia Pharmaceuticals USD 257.76M 778K Dec/2025
Agios Pharmaceuticals USD 18.09M 6.89M Dec/2025
Akebia Therapeutics USD 47.28M 1.7M Dec/2025
Alnylam Pharmaceuticals USD 829.31M 219.56M Dec/2025
AstraZeneca USD 12.39B 5M Dec/2025
BioMarin Pharmaceutical USD 713.01M 81.81M Dec/2025
Coherus Biosciences USD 8.7M 853K Dec/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Esperion Therapeutics USD 140.59M 94.57M Dec/2025
Halozyme Therapeutics USD 281.77M 2.41M Sep/2025
Illumina USD 759M 26M Dec/2025
Insmed USD 217.69M 106.25M Dec/2025
Ironwood Pharmaceuticals USD 85.24M 44.1M Jun/2025
J&J USD 16.6B 118M Dec/2025
Lexicon Pharmaceuticals USD 5.29M 8.88M Dec/2025
MacroGenics USD 31.11M 30.14M Dec/2025
MannKind USD 78.31M 76.21M Dec/2025
Merck USD 13.42B 431M Sep/2025
Moderna USD 226M 583M Dec/2025
Novartis USD 10.25B 570M Dec/2025
PTC Therapeutics USD 148.38M 39.31M Dec/2025
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Sarepta Therapeutics USD 43.55M 204.36M Dec/2025
Thermo Fisher Scientific USD 4.64B 419M Dec/2025
Ultragenyx Pharmaceutical USD 178M 46.06M Dec/2025
United Therapeutics USD 315.5M 286.6M Dec/2025
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024